A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma
HEPATOCELLULAR CARCINOMA
DRUG: Darinaparsin
Response Rate, 6 months
Survival (overall and progression free), 6 months|toxicities, 6 months
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma